Document Type : Original Article


1 National Institute of Genetic Engineering and Biotechnology, Tehran, Iran

2 Behavioral Sciences Research Center, lifestyle Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran



Colorectal cancer is the third most common cancer and the second leading cause of cancer deaths in the world. Risk factors such as obesity, low-fiber diet, sedentary, and alcohol have been implicated in the development of this cancer. Cells have many mechanisms in place to fight malignancy and cancer, one of which is the detoxification system that protect the cell against DNA damage. One of the essential components of this system is the glutathione s-transferase. In this study, the genotype of region -69 promoter of this gene in 150 colorectal cancer patients and 150 healthy people was investigated by the RFLP method. T/T genotype is significantly associated with colorectal cancer (P = 0.0001), C/T genotype did not show a significant association with colorectal cancer and its frequency was not significantly different in both healthy and patient groups (P = 0.074), Most genotypes in the two groups were homozygous C / C and did not show a significant association with colorectal cancer.


1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS,
Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J
Clin. 2017;67(3):177-193. doi: 10.3322/caac.21395 pmid:
2. Ansari R, Mahdavinia M, Sadjadi A, Nouraie M, Kamangar F,
Bishehsari F, et al. Incidence and age distribution of colorectal
cancer in Iran: results of a population-based cancer registry.
Cancer Lett. 2006;240(1):143-147. doi:
10.1016/j.canlet.2005.09.004 pmid: 16288832
3. Haggar FA, Boushey RP. Colorectal cancer epidemiology:
incidence, mortality, survival, and risk factors. Clin Colon Rectal
Surg. 2009;22(4):191-197. doi: 10.1055/s-0029-1242458
pmid: 21037809
4. Lee C, Raffaghello L, Longo VD. Starvation, detoxification,
and multidrug resistance in cancer therapy. Drug Resist Updat2012;15(1-2):114-122. doi: 10.1016/j.drup.2012.01.004
pmid: 22391012
5. Yao SJ, Wolfson SK. Blood and tissue detoxification apparatus.
Google Patents; 1976.
6. Salinas AE, Wong MG. Glutathione S-transferases-a review.
Curr Med Chem. 1999;6(4):279-310.
7. Dusinska M, Staruchova M, Horska A, Smolkova B, Collins A,
Bonassi S, et al. Are glutathione S transferases involved in DNA
damage signalling? Interactions with DNA damage and repair
revealed from molecular epidemiology studies. Mutat Res.
2012;736(1-2):130-137. doi:
10.1016/j.mrfmmm.2012.03.003 pmid: 22450146
8. Keen JH, Habig WH, Jakoby WB. Mechanism for the several
activities of the glutathione S-transferases. J Biol Chem.
1976;251(20):6183-6188. pmid: 977564
9. Townsend DM, Tew KD. The role of glutathione-S-transferase
in anti-cancer drug resistance. Oncogene. 2003;22(47):7369-
7375. doi: 10.1038/sj.onc.1206940 pmid: 14576844
10. Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S,
Kanda Y, et al. Influence of glutathione S-transferase A1
polymorphism on the pharmacokinetics of busulfan. Clin Chim
Acta. 2006;368(1-2):93-98. doi: 10.1016/j.cca.2005.12.011
pmid: 16448639
11. Sweeney C, Ambrosone CB, Joseph L, Stone A, Hutchins LF,
Kadlubar FF, et al. Association between a glutathione S-
transferase A1 promoter polymorphism and survival after
breast cancer treatment. Int J Cancer. 2003;103(6):810-814.
doi: 10.1002/ijc.10896 pmid: 12516103
12. Benito E, Stiggelbout A, Bosch FX, Obrador A, Kaldor J, Mulet
M, et al. Nutritional factors in colorectal cancer risk: a case-
control study in Majorca. Int J Cancer. 1991;49(2):161-167.
doi: 10.1002/ijc.2910490202 pmid: 1652565
13. Coles BF, Morel F, Rauch C, Huber WW, Yang M, Teitel CH,
et al. Effect of polymorphism in the human glutathione S-
transferase A1 promoter on hepatic GSTA1 and GSTA2
expression. Pharmacogenetics. 2001;11(8):663-669. doi:
10.1097/00008571-200111000-00004 pmid: 11692074.